Cargando…
Circulating miR-200 Family and CTCs in Metastatic Breast Cancer before, during, and after a New Line of Systemic Treatment
The extracellular circulating microRNA (miR)-200 regulates epithelial-mesenchymal transition and, thus, plays an essential role in the metastatic cascade and has shown itself to be a promising prognostic and predictive biomarker in metastatic breast cancer (MBC). Expression levels of the plasma miR-...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9455626/ https://www.ncbi.nlm.nih.gov/pubmed/36076930 http://dx.doi.org/10.3390/ijms23179535 |
_version_ | 1784785620270317568 |
---|---|
author | Fischer, Chiara Turchinovich, Andrey Feisst, Manuel Riedel, Fabian Haßdenteufel, Kathrin Scharli, Philipp Hartkopf, Andreas D. Brucker, Sara Y. Michel, Laura Burwinkel, Barbara Schneeweiss, Andreas Wallwiener, Markus Deutsch, Thomas M. |
author_facet | Fischer, Chiara Turchinovich, Andrey Feisst, Manuel Riedel, Fabian Haßdenteufel, Kathrin Scharli, Philipp Hartkopf, Andreas D. Brucker, Sara Y. Michel, Laura Burwinkel, Barbara Schneeweiss, Andreas Wallwiener, Markus Deutsch, Thomas M. |
author_sort | Fischer, Chiara |
collection | PubMed |
description | The extracellular circulating microRNA (miR)-200 regulates epithelial-mesenchymal transition and, thus, plays an essential role in the metastatic cascade and has shown itself to be a promising prognostic and predictive biomarker in metastatic breast cancer (MBC). Expression levels of the plasma miR-200 family were analyzed in relationship to systemic treatment, circulating tumor cells (CTC) count, progression-free survival (PFS), and overall survival (OS). Expression of miR-200a, miR-200b, miR-200c, miR-141, and miR-429, and CTC status (CTC-positive ≥ 5 CTC/7.5 mL) was assessed in 47 patients at baseline (BL), after the first completed cycle of a new line of systemic therapy (1C), and upon the progression of disease (PD). MiR-200a, miR-200b, and miR-141 expression was reduced at 1C compared to BL. Upon PD, all miR-200s were upregulated compared to 1C. At all timepoints, the levels of miR-200s were elevated in CTC-positive versus CTC-negative patients. Further, heightened miR-200s expression and positive CTC status were associated with poorer OS at BL and 1C. In MBC patients, circulating miR-200 family members decreased after one cycle of a new line of systemic therapy, were elevated during PD, and were indicative of CTC status. Notably, increased levels of miR-200s and elevated CTC count correlated with poorer OS and PFS. As such, both are promising biomarkers for optimizing the clinical management of MBC. |
format | Online Article Text |
id | pubmed-9455626 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94556262022-09-09 Circulating miR-200 Family and CTCs in Metastatic Breast Cancer before, during, and after a New Line of Systemic Treatment Fischer, Chiara Turchinovich, Andrey Feisst, Manuel Riedel, Fabian Haßdenteufel, Kathrin Scharli, Philipp Hartkopf, Andreas D. Brucker, Sara Y. Michel, Laura Burwinkel, Barbara Schneeweiss, Andreas Wallwiener, Markus Deutsch, Thomas M. Int J Mol Sci Article The extracellular circulating microRNA (miR)-200 regulates epithelial-mesenchymal transition and, thus, plays an essential role in the metastatic cascade and has shown itself to be a promising prognostic and predictive biomarker in metastatic breast cancer (MBC). Expression levels of the plasma miR-200 family were analyzed in relationship to systemic treatment, circulating tumor cells (CTC) count, progression-free survival (PFS), and overall survival (OS). Expression of miR-200a, miR-200b, miR-200c, miR-141, and miR-429, and CTC status (CTC-positive ≥ 5 CTC/7.5 mL) was assessed in 47 patients at baseline (BL), after the first completed cycle of a new line of systemic therapy (1C), and upon the progression of disease (PD). MiR-200a, miR-200b, and miR-141 expression was reduced at 1C compared to BL. Upon PD, all miR-200s were upregulated compared to 1C. At all timepoints, the levels of miR-200s were elevated in CTC-positive versus CTC-negative patients. Further, heightened miR-200s expression and positive CTC status were associated with poorer OS at BL and 1C. In MBC patients, circulating miR-200 family members decreased after one cycle of a new line of systemic therapy, were elevated during PD, and were indicative of CTC status. Notably, increased levels of miR-200s and elevated CTC count correlated with poorer OS and PFS. As such, both are promising biomarkers for optimizing the clinical management of MBC. MDPI 2022-08-23 /pmc/articles/PMC9455626/ /pubmed/36076930 http://dx.doi.org/10.3390/ijms23179535 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Fischer, Chiara Turchinovich, Andrey Feisst, Manuel Riedel, Fabian Haßdenteufel, Kathrin Scharli, Philipp Hartkopf, Andreas D. Brucker, Sara Y. Michel, Laura Burwinkel, Barbara Schneeweiss, Andreas Wallwiener, Markus Deutsch, Thomas M. Circulating miR-200 Family and CTCs in Metastatic Breast Cancer before, during, and after a New Line of Systemic Treatment |
title | Circulating miR-200 Family and CTCs in Metastatic Breast Cancer before, during, and after a New Line of Systemic Treatment |
title_full | Circulating miR-200 Family and CTCs in Metastatic Breast Cancer before, during, and after a New Line of Systemic Treatment |
title_fullStr | Circulating miR-200 Family and CTCs in Metastatic Breast Cancer before, during, and after a New Line of Systemic Treatment |
title_full_unstemmed | Circulating miR-200 Family and CTCs in Metastatic Breast Cancer before, during, and after a New Line of Systemic Treatment |
title_short | Circulating miR-200 Family and CTCs in Metastatic Breast Cancer before, during, and after a New Line of Systemic Treatment |
title_sort | circulating mir-200 family and ctcs in metastatic breast cancer before, during, and after a new line of systemic treatment |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9455626/ https://www.ncbi.nlm.nih.gov/pubmed/36076930 http://dx.doi.org/10.3390/ijms23179535 |
work_keys_str_mv | AT fischerchiara circulatingmir200familyandctcsinmetastaticbreastcancerbeforeduringandafteranewlineofsystemictreatment AT turchinovichandrey circulatingmir200familyandctcsinmetastaticbreastcancerbeforeduringandafteranewlineofsystemictreatment AT feisstmanuel circulatingmir200familyandctcsinmetastaticbreastcancerbeforeduringandafteranewlineofsystemictreatment AT riedelfabian circulatingmir200familyandctcsinmetastaticbreastcancerbeforeduringandafteranewlineofsystemictreatment AT haßdenteufelkathrin circulatingmir200familyandctcsinmetastaticbreastcancerbeforeduringandafteranewlineofsystemictreatment AT scharliphilipp circulatingmir200familyandctcsinmetastaticbreastcancerbeforeduringandafteranewlineofsystemictreatment AT hartkopfandreasd circulatingmir200familyandctcsinmetastaticbreastcancerbeforeduringandafteranewlineofsystemictreatment AT bruckersaray circulatingmir200familyandctcsinmetastaticbreastcancerbeforeduringandafteranewlineofsystemictreatment AT michellaura circulatingmir200familyandctcsinmetastaticbreastcancerbeforeduringandafteranewlineofsystemictreatment AT burwinkelbarbara circulatingmir200familyandctcsinmetastaticbreastcancerbeforeduringandafteranewlineofsystemictreatment AT schneeweissandreas circulatingmir200familyandctcsinmetastaticbreastcancerbeforeduringandafteranewlineofsystemictreatment AT wallwienermarkus circulatingmir200familyandctcsinmetastaticbreastcancerbeforeduringandafteranewlineofsystemictreatment AT deutschthomasm circulatingmir200familyandctcsinmetastaticbreastcancerbeforeduringandafteranewlineofsystemictreatment |